# Tor Biering-Sørensen: Phase 4 study closed enrollment, 168460 enrolled (Cardiovascular Disease, Dementia)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Tor Biering-Sørensen |
| Sponsor type | Academic and hospital |
| Study | Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia |
| NCT ID | NCT07485283 |
| Phase | Phase 4 |
| Status | active not recruiting |
| Conditions | Cardiovascular Disease; Dementia |
| Intervention types | biological |
| Target enrollment | 168460 |
| Site countries | Denmark |
| Posted | 2026-03-20 |
| Planned start | 2026-04-28 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-14 |
| Last update posted | 2026-10-14 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- 168460 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07485283). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.